Pasar al contenido principal

ESPEFICIACION NEURONAL DESDE CELULAS MADRE NEURALES. ¿POR QUE SOY UNICA?

BFU2016-78327-P

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D (Excelencia / Generación de Conocimiento)
Año convocatoria 2016
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD AUTONOMA DE MADRID

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Structural stability of SARS-CoV-2 3CLpro and identification of quercetin as an inhibitor by experimental screening

  • Abian, Olga
  • Ortega-Alarcón, David
  • Jiménez-Alesanco, Ana
  • Ceballos-Laita, Laura
  • Vega, Sonia
  • Reyburn, H. T.
  • Rizzuti, Bruno
  • Velázquez-Campoy, Adrián
The global health emergency generated by coronavirus disease 2019 (COVID-19) has prompted the search for preventive and therapeutic treatments for its pathogen, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). There are many potential targets for drug discovery and development to tackle this disease. One of these targets is the main protease, Mpro or 3CLpro, which is highly conserved among coronaviruses. 3CLpro is an essential player in the viral replication cycle, processing the large viral polyproteins and rendering the individual proteins functional. We report a biophysical characterization of the structural stability and the catalytic activity of 3CLpro from SARS-CoV-2, from which a suitable experimental in vitro molecular screening procedure has been designed. By screening of a small chemical library consisting of about 150 compounds, the natural product quercetin was identified as reasonably potent inhibitor of SARS-CoV-2 3CLpro (Ki ~ 7 μM). Quercetin could be shown to interact with 3CLpro using biophysical techniques and bind to the active site in molecular simulations. Quercetin, with well-known pharmacokinetic and ADMET properties, can be considered as a good candidate for further optimization and development, or repositioned for COVID-19 therapeutic treatment., This work was supported by Fundación hna; Miguel Servet Program from Instituto de Salud Carlos III (CPII13/00017 to O.A.); Fondo de Investigaciones Sanitarias from Instituto de Salud Carlos III, and European Union (ERDF/ESF, ‘Investing in your future’) (PI18/00343 to O.A. and a FIS Research Contract to L.C.L.); Spanish Ministry of Economy and Competitiveness (BFU2016-78232-P to A.V.C. and SAF2017-83265-R to H.T.R.); Spanish Ministry of Science, Innovation and Universities (FPI Predoctoral Research Contract BES-2017-080739 to D.O.A.); the Spanish National Research Council (CSIC, project 202020E079); Diputación General de Aragón (Predoctoral Research Contract 2019 to A.J.A., ‘Protein Targets and Bioactive Compounds Group’ E45_20R to A.V.C., ‘Digestive Pathology Group’ B25_20R to O.A.); Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBERehd). The proteomic analysis was performed in the Proteomics Facility of The Spanish National Center for Biotechnology (CNB-CSIC) that belongs to ProteoRed, PRB3-ISCIII, supported by grant PT17/0019., Peer reviewed